In all, our results suggest that not only do patients with ACPA+ RA and ACPA− RA portray serological differences in autoantibody abundances, but also lower abundances of certain autoantibodies (compared with controls) could potentially be a novel hallmark of RA. This evidence concerns the gene PRTN3 and rheumatoid arthritis.